Etripamil is a small molecule commercialized by Milestone Pharmaceuticals, with a leading Pre-Registration program in Supraventricular Tachycardia. According to Globaldata, it is involved in 13 clinical trials, of which 8 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Etripamil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for Etripamil is expected to reach an annual total of $458 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Etripamil Overview

Etripamil (MSP-2017) is under development for the treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), and atrial fibrillation. The drug candidate is a short-acting therapeutic administered by intranasal route as a spray. It is a new chemical entity and acts by targeting calcium channel.

It was under development for stable angina.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Milestone Pharmaceuticals Overview

Milestone Pharmaceuticals is a Pharmaceutical company. It develops novel small molecule therapeutics. The company undertakes the development of small molecule therapeutics based on clinically validated mechanisms, for the treatment of cardiovascular diseases. It’s lead product etripamil, is a potent short-acting calcium channel antagonist for the systemic treatment of cardiovascular conditions such as angina, paroxysmal supraventricular tachycardia and atrial arrhythmias. It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient. It operates in the US and Canada. Milestone Pharmaceuticals is headquartered in Saint-Laurent, Quebec, Canada.
The company reported revenues of (US Dollars) US$1 million for the fiscal year ended December 2023 (FY2023), a decrease of 80% over FY2022. The operating loss of the company was US$61.1 million in FY2023, compared to an operating loss of US$59.6 million in FY2022. The net loss of the company was US$59.7 million in FY2023, compared to a net loss of US$58.4 million in FY2022.

For a complete picture of Etripamil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.